Rivaroxaban vs Apixaban and Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation

被引：0
|
作者：
Ray, Wayne A. [1 ]
Murray, Katherine T. [2 ]
机构：
[1] Vanderbilt Univ, Dept Hlth Policy, Sch Med, Nashville, TN USA
[2] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2022年 / 327卷 / 13期
关键词：
D O I：
10.1001/jama.2022.1425
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1290 / 1290
页数：1
相关论文
共 50 条
  • [21] Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation
    Steppich, B.
    Dobler, F.
    Brendel, L. C.
    Hessling, G.
    Braun, S. L.
    Steinsiek, A. L.
    Deisenhofer, I.
    Hyseni, A.
    Roest, M.
    Ott, I.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2017, 43 (04) : 490 - 497
  • [22] Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation
    B. Steppich
    F. Dobler
    L. C. Brendel
    G. Hessling
    S. L. Braun
    A. L. Steinsiek
    I. Deisenhofer
    A. Hyseni
    M. Roest
    I. Ott
    Journal of Thrombosis and Thrombolysis, 2017, 43 : 490 - 497
  • [23] Real-World Rivaroxaban and Apixaban Levels in Asian Patients With Atrial Fibrillation
    Lin, Shin-Yi
    Kuo, Ching-Hua
    Yeh, Shin-Joe
    Tsai, Li-Kai
    Liu, Yen-Bin
    Huang, Chih-Fen
    Tang, Sung-Chun
    Jeng, Jiann-Shing
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (01) : 278 - 286
  • [24] Comparison of bleeding and ischemic events with apixaban vs. rivaroxaban in triple antithrombotic therapy regimens
    Chilbert, Maya R.
    Woodruff, Ashley E.
    Saber, Marissa
    Goriacko, Pavel
    Sinnet, Mark
    Jacobs, David
    BLOOD COAGULATION & FIBRINOLYSIS, 2023, 34 (06) : 370 - 376
  • [25] Comparative effectiveness and safety of apixaban and rivaroxaban in cirrhosis and atrial fibrillation
    Simon, Tracey G.
    Zhang, Yichi
    Mastrorilli, Julianna
    Cervone, Alexander
    Lin, Kueiyu Joshua
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 56 - 57
  • [26] Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban
    Giorgi, Mariano A.
    Cohen Arazi, Hernan
    Gonzalez, Claudio D.
    Di Girolamo, Guillermo
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (04) : 567 - 577
  • [27] Apixaban in Patients with Atrial Fibrillation
    Connolly, Stuart J.
    Eikelboom, John
    Joyner, Campbell
    Diener, Hans-Christoph
    Hart, Robert
    Golitsyn, Sergey
    Flaker, Greg
    Avezum, Alvaro
    Hohnloser, Stefan H.
    Diaz, Rafael
    Talajic, Mario
    Zhu, Jun
    Pais, Prem
    Budaj, Andrzej
    Parkhomenko, Alexander
    Jansky, Petr
    Commerford, Patrick
    Tan, Ru San
    Sim, Kui-Hian
    Lewis, Basil S.
    Van Mieghem, Walter
    Lip, Gregory Y. H.
    Kim, Jae Hyung
    Lanas-Zanetti, Fernando
    Gonzalez-Hermosillo, Antonio
    Dans, Antonio L.
    Munawar, Muhammad
    O'Donnell, Martin
    Lawrence, John
    Lewis, Gayle
    Afzal, Rizwan
    Yusuf, Salim
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (09): : 806 - 817
  • [28] Influence of ABCB1 Gene Polymorphism on Rivaroxaban Blood Concentration and Hemorrhagic Events in Patients With Atrial Fibrillation
    Wang, Yan
    Chen, Min
    Chen, Hui
    Wang, Fang
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [29] Apixaban in Patients with Atrial Fibrillation
    Lynch, Donald R., Jr.
    NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (24): : 2362 - 2363
  • [30] Hemostasis POC tests are affected by dabigatran, rivaroxaban and apixaban treatments in patients with atrial fibrillation
    Paniccia, R.
    Marcucci, R.
    Priora, R.
    Liotta, A. Alessandrello
    Poli, D.
    Lembo, G.
    Ahmed, Y.
    Fanciullacci, C.
    Pazzi, M.
    Abbate, R.
    EUROPEAN HEART JOURNAL, 2015, 36 : 1080 - 1080
12345